

EDITORIAL

Open Access



25 years of research and therapy in arthritis

Harris Perlman^{1*} and Christopher D. Buckley²

When it was established 25 years ago by Peter Lipsky and Ravinder Maini, Rheumatology as a speciality, like Cinderella, had just arrived at the ball. Anti TNF therapy was revolutionizing the treatment of not just inflammatory arthritis, but many other immune mediated inflammatory diseases. For the first time people with arthritis could dream of a cure. But to cure a disease requires an understanding of its cause. So two years after we took over as editors in Chief of *Arthritis Research and Therapy* we outlined how we wanted the new aims and scope of the Journal to be <https://arthritis-research.biomedcentral.com/articles/https://doi.org/10.1186/s13075-018-1518-y> to reflect this desire to aim for a cure. We focussed on two themes we wanted to promote: discovery research and experimental therapy. Since 2018 there has been a revolution in the basic, translational and clinical research that has been considered for publication by the journal, driven by advances in spatial technology and single cell analysis as well as artificial intelligence and bioinformatics. All these approaches have helped expose the mechanisms that drive pathogenicity. The ability to sample human tissue using minimally invasive techniques and to do so over time has allowed our authors to submit manuscripts that explore causal mechanisms in the real model organism; humans, in real clinical studies, rather than having to extrapolate from preclinical models in mice. This combined with the explosion in cell-based depletion strategies using CAR T cell therapies, means that our Journal is well placed to continue to lead the way in publishing outstand-

ing research and new studies that explore novel therapies in arthritis into the next 25 years. To do this will require the continued engagement of our international community of outstanding and expert section editors, associate editors and editorial board as well as the selfless commitment of our reviewers. The new editorial management system (SNAPP: Springer Nature's article Processing platform) has improved our governance and editorial consistency and enhanced the turnaround rate for manuscripts. It also allows us to monitor plagiarism and malpractice during the submission and review process using state of the art AI systems across the full range of Springer Nature Journals. We want to thank all those colleagues who have helped and continue to help the journal become a trusted, internationally respected journal that expands the boundaries of musculoskeletal disease research.

Author contributions

HP and CB cowrote the manuscript.

Declarations

Competing Interests

There are no competing interests.

Published online: 02 April 2025

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

*Correspondence:

Harris Perlman
h-perlman@northwestern.edu

¹Department of Medicine, Division of Rheumatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

²Kennedy Institute of Rheumatology, , University of Oxford, Roosevelt Drive, Headington, Oxford, UK



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.